Opinion|Videos|May 17, 2024
COPD Traits Associated with Phenotypes
The expert panel offers insights on the concept of extending phenotypes into treatable traits in patients with COPD.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- COPD has long been recognized as involving an amplified innate immune response; there is growing recognition that some patients have type 2 inflammation.
- What do we know about the role of type 2 inflammation in COPD and why is this important?
- What do we know about the role of type 2 inflammation in COPD and why is this important?
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.
HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.
With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.
The guideline chair answers key questions on new ferritin cutoffs, symptoms without anemia, inflammation, and lab reporting.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity
3
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
4
Why "Normal" Ferritin Can Miss Iron Deficiency, With Jacquelyn Powers, MD, MS
5